Panitumumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Panitumumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
322
Registered trials
407
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Panitumumab can convert its Monoclonal antibody profile and EGFR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Panitumumab (query alias: panitumumab) |
|---|---|
| Modality / target | Monoclonal antibody; EGFR; EGFR antagonists |
| Highest global status | Approved |
| Originator | Amgen, Inc. |
| Active developers | Amgen, Inc., Amgen Europe BV, Stanford University |
The MCP disease footprint includes KRAS G12C mutant Colorectal Cancer, KRAS Wild-type Colorectal Cancer, KRAS mutant Colorectal Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07124884 | Phase 2 | Not yet recruiting | 300 | Percentage of patient alive or without progression 8 months after inclusion. |
| NCT07659795 | Phase 2 | Recruiting | 150 | Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only |
| NCT07172919 | Phase 2 | Recruiting | 14 | Number of Participants with Treatment-Emergent Adverse Events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Propensity score–matched analysis of trifluridine-tipiracil plus bevacizumab (FTD/TPI+Bev) vs anti-EGFR re-treatment in pretreated metastatic colorectal cancer (mCRC).
Not Applicable; n=175; evaluation: Positive. Reported fields: mOS = 11.6 month ; mOS = 13.1 month
A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial).
Phase 2; n=30; evaluation: Positive. Reported fields: RR = 16.7 % ; RR = 6.7 % ( 1.8 - 16.8); -
Genomic biomarkers of primary resistance to anti-EGFR monoclonal antibodies (mAbs) by comprehensive genomic profiling (CGP) in EGFR-amplified (ampl) advanced gastroesophageal adenocarcinoma (aGEA) and correlative analysis from a single-arm study with panitumumab.
Not Applicable; n=130; evaluation: Negative. Reported fields: -; DCR = 18.2 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Panitumumab addresses KRAS G12C mutant Colorectal Cancer, KRAS Wild-type Colorectal Cancer, KRAS mutant Colorectal Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2016-09-16 | Dr. Reddy’s Expands Strategic Collaboration with Amgen in India | Approved | Financial terms not disclosed |
| 2016-06-24 | Takeda Revises Collaboration Agreement with Amgen, Returning the Development and Commercialization Rights of Molecules / Products for Japan | Phase 2 | Financial terms not disclosed |
| 2013-05-09 | Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combinations of a b-RAF inhibitor, and an Anti-EGFR antibody for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical combination of spirocyclic aryl phosphorus oxide and Anti-EGFR antibody”. The milestone feed surfaced a patent-application signal described as “Sotorasib and an EGFR antibody for treating cancer comprising a KRAS g12c mutation”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
